Form 4 for AMRX Amneal Pharmaceuticals, Inc.
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001209191-22-016050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-03 | 2022-03-01 | AMRX | Konidaris Tasos | EVP, CFO | M - OptEx | — | +36.2K | 123.9K | +41% | — |
| D | 2022-03-03 | 2022-03-01 | AMRX | Konidaris Tasos | EVP, CFO | M - OptEx | $0.00 | -36.2K | 108.6K | -25% | $0 |
| DM | 2022-03-03 | 2022-03-03 | AMRX | Konidaris Tasos | EVP, CFO | A - Grant | $0.00 | +543.5K | 181.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-03-01 | M | A | 36,197 | — | 123,916 | D | — | — | (F1) Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| 2 | Derivative | Restricted Stock Units | 2022-03-01 | M | D | 36,197 | $0.00 | 108,591 | D | — · — to — | 36,197 Class A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. (F3) On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 3 | Derivative | Performance-Based Restricted Stock Units | 2022-03-03 | A | A | 362,318 | $0.00 | 362,318 | D | — · — to — | 362,318 Class A Common Stock | (F6) Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. (F5) Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| 4 | Derivative | Restricted Stock Units | 2022-03-03 | A | A | 181,159 | $0.00 | 181,159 | D | — · — to — | 181,159 Class A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. (F4) The restricted stock units vest in four equal annual installments beginning on March 3, 2023. |